Pyxis Oncology, Inc. Increase (Decrease) in Contract with Customer, Liability
Pyxis Oncology, Inc. (PYXS) reported Increase (Decrease) in Contract with Customer, Liability of -$7.66 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-03-23
- Pyxis Oncology, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Pyxis Oncology, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was $0.00.
- Pyxis Oncology, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was $0.00.
- Pyxis Oncology, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was -$7.66M.
- Pyxis Oncology, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$7.66M, a 867.54% decline from fiscal 2023.
- Pyxis Oncology, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $998.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | -$7.66M 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | -$7.66M 10-Q · filed 2025-11-03 | -$7.19M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$7.66M 10-Q · filed 2025-08-14 | -$7.19M derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$7.66M 10-Q · filed 2025-05-15 | -$7.19M derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $471.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $998.00K 10-K · filed 2025-03-18 | ||
| 2023-09-30 | $527.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |